ZOETIS INC (ZTS) Stock News
NYSE:ZTS - New York Stock Exchange, Inc. - US98978V1035 - Common Stock - Currency: USD
ZTS Latest News, Press Relases and Analysis
Which S&P500 stocks are gapping on Tuesday?
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?
On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion. Total revenue increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio and an early contribution from the U.S. launch
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting.
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of 5.71% and 1.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CRON
Zoetis’s (NYSE:ZTS) Q1: Beats On Revenue, Full-Year Sales Guidance is Optimistic
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.8% above analysts’ consensus estimates.
Mentions: PFE
Zoetis Announces First Quarter 2025 Results
Jim Cramer Warns on Tempus AI (TEM): “Diagnostics With no Dough? I’m Out”
We recently published a list of Jim Cramer’s Thoughts on These 13 Stocks. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other stocks that Jim Cramer discussed. On Thursday’s episode of Mad Money, Jim Cramer voiced his exasperation over the skepticism surrounding AI infrastructure as […]
Zoetis (ZTS) Q1 Earnings: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results tomorrow before market hours. Here’s what investors should know.
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
MKKGY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
Zoetis (ZTS) concluded the recent trading session at $156.40, signifying a +0.62% move from its prior day's close.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: CPRX
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: NBIX
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
3 Growth Stocks Down 30% or More to Buy Right Now
Pinpointing strong bargains in the stock market is key to success, and the market is full of them right now. Three companies that are down more than 30% from their all-time highs and look like excellent buys are Nvidia (NASDAQ: NVDA), Taiwan Semiconductor (NYSE: TSM), and ASML (NASDAQ: ASML). As a quick overview of the supply chain, Nvidia places Taiwan Semiconductor's chips in its GPUs (graphics processing units), which have been the primary computing unit deployed by the AI hyperscalers.
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio. With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).
Is Archer Aviation Stock a Millionaire Maker?
Archer Aviation (NYSE: ACHR) has built a futuristic airplane that can now be seen buzzing around test sites. Here's what you need to know if you are looking at Archer Aviation today. When digging into the story of Archer Aviation, you have to step back and give the company some respect.
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
Investors have been waiting nearly a decade to score a good deal on this healthcare star.
Mentions: PFE
Zoetis (ZTS) Advances But Underperforms Market: Key Facts
In the most recent trading session, Zoetis (ZTS) closed at $152.30, indicating a +0.92% shift from the previous trading day.
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
Zoetis (NYSE: ZTS) is a leading animal healthcare company offering over 300 medicines, vaccines, and other precision health products to care for companion animals and livestock globally. Since its spin-off from Pfizer in 2013, Zoetis has delivered an annualized total return of 15%, demonstrating the market-beating potential of what might look like a steady-Eddie investment at first glance. Following this decline, though, Zoetis now trades at a price-to-earnings (P/E) ratio of 27 -- its lowest mark in a decade.
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administration. Zoetis (NYSE: ZTS) is a global leader in animal health, with an extensive portfolio of medicines, vaccines, and diagnostic products for livestock and pets. The company's diversification, covering 17 products generating over $100 million in annual revenue, including several best-in-class treatments, underscores its appeal as an investment.
4 Top Tech Stocks to Buy Right Now
Amidst the market volatility due to tariffs and trade tensions, many top tech companies are now selling at much more attractive valuations than just a few months ago. Pinterest (NYSE: PINS) operates an online vision board that has more than 550 million monthly active users (MAU) across the globe. Better monetizing its user base is a huge opportunity for Pinterest, especially in the markets outside the U.S. and Europe where more than half its user base resides.
Zoetis Inc. (ZTS): Among Stocks with Buy Ratings that Hedge Funds Love
We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a look at where Zoetis Inc. (NYSE:ZTS) stands against other stocks with buy ratings that hedge funds love. The U.S. stock market has been in chaos ever since President Trump announced his […]